fbpx
QQQ
-1.91
368.39
-0.52%
DIA
-1.32
352.14
-0.38%
SPY
-2.11
442.76
-0.48%
TLT
+ 0.70
148.12
+ 0.47%
GLD
-1.36
172.53
-0.79%

HAE, ELGX, XRAY...BMO Capital Highlights This Week's MedTech Earnings

by
August 1, 2016 3:14 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Halfway through earnings season and analysts at BMO Capital Markets have noticed the following themes regarding MedTech companies:

  • Q2 has no clear theme of upward revisions, like what the market saw in Q1
  • Companies with large market cap have beat revenue, and virtually all have beaten EPS estimates also

In a note to investors, BMO highlighted earnings this week in MedTech, noting that they are now focusing more on small-cap names.

Monday 8/1

  • Haemonetics Corporation (NYSE: HAE) – Reported pre-market (PM), Q1 EPS $0.25 vs $0.29 estimated, revenues of $209.96M vs $205.24M estimated
  • Glaukos Corp (NYSE: GKOS) – After hours (AH)
  • Orthofix International NV (NASDAQ: OFIX) – AH

Tuesday 8/2

  • Mazor Robotics Ltd (NASDAQ: MZOR) – PM
  • Wright Medical Group (NASDAQ: WMGI) – AH
  • Endologix, Inc (NASDAQ: ELGX) – AH
  • DexCom, Inc (NASDAQ: DXCM) – AH
  • Intersect ENT Inc (NASDAQ: XENT) – AH

Wednesday 8/3

  • Insulet Corporation (NASDAQ: PODD) – AH
  • STAAR Surgical Company (NASDAQ: STAA) – AH
  • Cardiovascular Systems Inc (NASDAQ: CSII) – AH
  • K2M Group Holdings Inc (NASDAQ: KTWO) – AH

Thursday 8/4

  • Becton Dickinson and Co (NYSE: BDX) – PM
  • Hill-Rom Holdings, Inc (NYSE: HRC) – PM
  • Rewalk Robotics Ltd (NASDAQ: RWLK) – PM
  • DENTSPLY SIRONA Inc (NASDAQ: XRAY) – PM
  • AtriCure Inc (NASDAQ: ATRC) – AH

BMO expects fundamental to be in the spotlight as the remainder of earnings season unfolds.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Needham Maintains AtriCure as Top Small/Mid-Cap Pick; Warns on Lower Revenue for Q4 Following Management Preannouncement However Highlights Upcoming Data from aMAZE Trial within Late 2021 as Major Catalyst with Near-Term Growth Driven by New Products

Canaccord Analysts Recommend 'Aggressively Buying' AtriCure After Sell-Off

UPDATE: Piper Jaffray Upgrades AtriCure to Overweight on New Management Confidence

UPDATE: Piper Jaffray Downgrades AtriCure from Overweight to Neutral